CompaniesOrexigen Therapeutics

Orexigen Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

BankruptBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (19)
View all

Total Trials

19

As Lead Sponsor

18

As Collaborator

1

Total Enrollment

15,834

By Phase

PHASE4: 2PHASE1: 3PHASE3: 6PHASE2: 8

By Status

COMPLETED: 14TERMINATED: 4WITHDRAWN: 1
Clinical Trials Pipeline19 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Today
NCT01601704
Hover over trial bars to see details

Recent Trials

NCT04399395Collaborator
Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery
PHASE4Withdrawn
Started: Nov 1, 2020 · Completed: Dec 31, 2022
NCT02735603Lead Sponsor
Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants
PHASE1Completed
84 participants
Started: Apr 30, 2016 · Completed: Oct 31, 2016
NCT02745912Lead Sponsor
Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants
PHASE1Completed
30 participants
Started: Apr 30, 2016 · Completed: Aug 31, 2016
NCT02638129Lead Sponsor
Naltrexone/Bupropion Cardiovascular Outcomes Study
PHASE4Terminated
67 participants
Started: Jan 31, 2016 · Completed: Jun 30, 2016
NCT02259179Lead Sponsor
Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers
PHASE1Completed
80 participants
Started: Sep 30, 2014 · Completed: Dec 31, 2014
View all 19 trials →